| Adagene Appoints John Maraganore, Ph.D. as Executive Advisor |
- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. “Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells. |
globenewswire.com |
2025-04-28 12:00:00 |
Czytaj oryginał (ang.) |
| Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting |
SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, IL, May 30 - June 3. |
globenewswire.com |
2025-04-23 14:05:00 |
Czytaj oryginał (ang.) |
| Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update |
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses |
globenewswire.com |
2025-03-24 10:00:00 |
Czytaj oryginał (ang.) |
| Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit |
SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its presentation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025. The summit, designed for all-size pharma/biotech companies, academia and investors seeking to enable a patient's immune system to eradicate cancer, provides the opportunity to hear directly from science and business stakeholders on the latest data impacting the field of immuno-oncology. |
globenewswire.com |
2025-03-13 10:00:00 |
Czytaj oryginał (ang.) |
| Adagene to Present at Leerink's Global Healthcare Conference 2025 |
SAN DIEGO and SUZHOU, China, March 06, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in one-on-one investor meetings and provide a corporate update at Leerink's Global Healthcare Conference 2025, taking place March 10-12 in Miami, Florida. |
globenewswire.com |
2025-03-06 10:00:00 |
Czytaj oryginał (ang.) |
| Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer |
- Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced an investigator initiated (IIT) Phase 2 neoadjuvant trial of ADG126 for patients with stage II or stage III colorectal cancer. The new study (NCT06846268), led by primary investigator Dr. Yong Wei Peng, Senior Consultant at the Department of Haematology-Oncology, National University Cancer Institute, Singapore, is expected to begin patient enrollment in April 2025. |
globenewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso, |
Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering. |
globenewswire.com |
2025-01-29 08:14:00 |
Czytaj oryginał (ang.) |
| Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium |
SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will share updated clinical data from ADG126 in microsatellite stable colorectal cancer (MSS CRC) at the ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA on Saturday, January 25, 2025. |
globenewswire.com |
2025-01-21 19:00:00 |
Czytaj oryginał (ang.) |
| Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? |
Here is how Adagene Inc. Sponsored ADR (ADAG) and Editas Medicine (EDIT) have performed compared to their sector so far this year. |
zacks.com |
2025-01-08 12:41:29 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Adagene (ADAG) This Year? |
Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year. |
zacks.com |
2024-12-06 12:41:07 |
Czytaj oryginał (ang.) |
| Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? |
Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year. |
zacks.com |
2024-11-20 12:41:32 |
Czytaj oryginał (ang.) |
| Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting |
- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade - |
globenewswire.com |
2024-11-07 12:01:00 |
Czytaj oryginał (ang.) |
| Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting |
SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced poster presentations at the upcoming SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. |
globenewswire.com |
2024-10-09 10:00:00 |
Czytaj oryginał (ang.) |
| Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) |
- Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab - |
globenewswire.com |
2024-09-16 07:01:00 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Adagene (ADAG) This Year? |
Here is how Adagene Inc. Sponsored ADR (ADAG) and DaVita HealthCare (DVA) have performed compared to their sector so far this year. |
zacks.com |
2024-09-11 14:45:44 |
Czytaj oryginał (ang.) |
| Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? |
Here is how Adagene Inc. Sponsored ADR (ADAG) and DaVita HealthCare (DVA) have performed compared to their sector so far this year. |
zacks.com |
2024-08-26 14:41:17 |
Czytaj oryginał (ang.) |
| Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September |
SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024. |
globenewswire.com |
2024-07-12 11:00:00 |
Czytaj oryginał (ang.) |
| Adagene to Present at Investor Conferences in June |
SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024. |
globenewswire.com |
2024-05-22 20:45:00 |
Czytaj oryginał (ang.) |
| Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update |
- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in combination with anti-PD-1 - |
globenewswire.com |
2024-03-29 11:00:00 |
Czytaj oryginał (ang.) |
| Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board |
- Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - |
globenewswire.com |
2024-03-07 18:01:00 |
Czytaj oryginał (ang.) |
| Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 |
SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida. |
globenewswire.com |
2024-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) |
- Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference - |
globenewswire.com |
2024-02-09 08:00:00 |
Czytaj oryginał (ang.) |
| Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) |
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy - |
globenewswire.com |
2024-01-16 19:01:00 |
Czytaj oryginał (ang.) |
| Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium |
- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this proven immunotherapy target - |
globenewswire.com |
2024-01-04 07:00:00 |
Czytaj oryginał (ang.) |
| Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023 |
- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab – |
globenewswire.com |
2023-11-03 14:00:00 |
Czytaj oryginał (ang.) |
| Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting |
- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort – |
globenewswire.com |
2023-10-12 12:00:00 |
Czytaj oryginał (ang.) |
| Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? |
Here is how Adagene Inc. Sponsored ADR (ADAG) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year. |
zacks.com |
2023-09-27 15:17:57 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Adagene (ADAG) This Year? |
Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year. |
zacks.com |
2023-09-07 15:16:59 |
Czytaj oryginał (ang.) |
| Adagene to Present at Investor and Scientific Conferences in September |
– Adagene's CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies – |
globenewswire.com |
2023-09-07 10:00:00 |
Czytaj oryginał (ang.) |